
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 21, 2024, titled "Glenmark and BeiGene Enter into an Agreement for Marketing and Distribution of Tislelizumab and Zanubrutinib in India".
Filed with NSE ·

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 21, 2024, titled "Glenmark and BeiGene Enter into an Agreement for Marketing and Distribution of Tislelizumab and Zanubrutinib in India".
6ix hasn’t read this filing yet.
Glenmark Pharmaceuticals Limited on 6ix
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals